Weiwei Hu

Weiwei Hu is the Associate Vice President of Bioprocess Development and Operation at Eli Lilly and Company, where they focus on developing biologics across various modalities. With extensive experience in CMC and a proven track record in leading high-performance teams, Weiwei has previously served as Vice President at both WuXi Biologics and WuXi Advanced Therapies. Their background includes significant roles at Biogen Idec and Celgene, where they contributed to cell culture process development and regulatory filing support. Weiwei holds a PhD in Chemical Engineering from The Ohio State University and is currently pursuing a Master’s degree in Biochemical Engineering at The East China University of Science and Technology.